On 25 June Professor Louise Emmet will make an oral presentation of LuPIN data to the SNMMI annual meeting in California. We already know from the abstract that LuPSMA + Veyonda achieved a 75% response at 800 mg after two shots per patient. Graham Kelly will attend the presentation.
I am also looking forward to data from the 1200 mg expansion-cohort in the DAART-1 trial, together with a read-out on the durability of responses to treatment at lower doses, which should be known in late July/early August IIRC. It is quite remarkable, in my opinion, that DARRT-type therapy typically takes just two weeks; does not require admission to a hospital; is safe to use; and can be repeated if required..
The latest corporate presentation makes a number of references to STING agonists, so I thought I would do some research…
It appears that STING activation increases the likelihood of abscopal responses, which explains why at least five companies have a STING agonist undergoing clinical trials. Of these, Merck, Aduro, Codiac and Synlogic compounds need to be injected directly into a tumour, with poor results so far. Noxopharm is the fifth company, with a critical difference: Veyonda is the only STING agonist in clinical trials that travels around the body.
GSK thinks this is the key to success. See https://www.marketscreener.com/GLAX...ist-could-overcome-delivery-hurdles-27569305/
Add to My Watchlist
What is My Watchlist?
